Hypertension Diagnostics EBITDA vs. Price To Sales

HDIIDelisted Stock  USD 0  0.0008  38.10%   
Based on Hypertension Diagnostics' profitability indicators, Hypertension Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Hypertension Diagnostics' ability to earn profits and add value for shareholders.
For Hypertension Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hypertension Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hypertension Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hypertension Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hypertension Diagnostics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Please note, there is a significant difference between Hypertension Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hypertension Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hypertension Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hypertension Diagnostics Price To Sales vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hypertension Diagnostics's current stock value. Our valuation model uses many indicators to compare Hypertension Diagnostics value to that of its competitors to determine the firm's financial worth.
Hypertension Diagnostics is one of the top stocks in ebitda category among its peers. It also is one of the top stocks in price to sales category among its peers . The ratio of EBITDA to Price To Sales for Hypertension Diagnostics is about  478,425 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hypertension Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hypertension Diagnostics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Hypertension Price To Sales vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Hypertension Diagnostics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
72.29 K
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Hypertension Diagnostics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
0.15 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Hypertension Price To Sales Comparison

Hypertension Diagnostics is currently under evaluation in price to sales category among its peers.

Hypertension Diagnostics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hypertension Diagnostics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hypertension Diagnostics will eventually generate negative long term returns. The profitability progress is the general direction of Hypertension Diagnostics' change in net profit over the period of time. It can combine multiple indicators of Hypertension Diagnostics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange.

Hypertension Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hypertension Diagnostics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hypertension Diagnostics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hypertension Diagnostics' important profitability drivers and their relationship over time.

Use Hypertension Diagnostics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hypertension Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hypertension Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Hypertension Diagnostics Pair Trading

Hypertension Diagnostics Pair Trading Analysis

The ability to find closely correlated positions to Hypertension Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hypertension Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hypertension Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hypertension Diagnostics to buy it.
The correlation of Hypertension Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hypertension Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hypertension Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hypertension Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Hypertension Diagnostics position

In addition to having Hypertension Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Processed Foods Thematic Idea Now

Processed Foods
Processed Foods Theme
Companies producing and distributing processed foods to retail sectors. The Processed Foods theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Processed Foods Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Hypertension Pink Sheet

If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets